Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.4K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.4K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

1.9K
1.9K
Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs01:20

Bioequivalence Experimental Study Designs: Completely Randomized and Randomized Block Designs

386
Bioequivalence experimental study designs are crucial methodologies used in evaluating and comparing the bioavailability of different drug products. These designs are categorized into various types: completely randomized, randomized block, repeated measures, cross and carry-over, and Latin square designs.Completely randomized designs involve randomly allocating treatments to all subjects participating in the experiment. This allocation is achieved by assigning unique random numbers to subjects...
386
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches01:23

Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches

565
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
565
Bioequivalence of Drugs: Drugs with Multiple Indications01:09

Bioequivalence of Drugs: Drugs with Multiple Indications

219
The concept of therapeutic equivalence (TE) in drugs with multiple indications is complex. A generic drug may be therapeutically equivalent to a brand-name product for one specific indication, but this doesn't necessarily mean it's equivalent for all other indications. Evidence of TE in one patient group and bioequivalence shown in healthy volunteers can support—but not confirm—TE for other indications. However, definitive proof requires individual clinical studies for each...
219
Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs01:15

Bioequivalence Experimental Study Designs: Repeated Measures, Cross-Over, Carry-Over, and Latin Square Designs

395
Bioequivalence experimental study designs play a pivotal role in testing the effectiveness of various treatments. Key among these are the repeated measures, cross-over, carry-over, and Latin square designs. In the repeated measures design, each subject receives all treatments, allowing for temporal comparisons. This type of design is useful in reducing variability but requires careful planning to avoid bias.The cross-over design, an economical method, involves sequential administration of...
395

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Smac deficiency affects endoplasmic reticulum stress-induced apoptosis in human colon cancer cells.

Molecular and cellular pharmacology·2011
Same author

RanGTPase: A Key Regulator of Nucleocytoplasmic Trafficking.

Molecular and cellular pharmacology·2011
Same author

Sulindac Sulfide Differentially Induces Apoptosis in Smac-Proficient and -Deficient Human Colon Cancer Cells.

Molecular and cellular pharmacology·2011
Same author

[Analysis of Differentially Expressed Proteins in Self-Paired Sera of Advanced Non-small Cell Lung Cancer Patients Responsive to Gefinitib.].

Zhongguo fei ai za zhi = Chinese journal of lung cancer·2010
Same author

Pooled versus individual genotyping in a breast cancer genome-wide association study.

Genetic epidemiology·2010
Same author

Structural basis for methylarginine-dependent recognition of Aubergine by Tudor.

Genes & development·2010

Related Experiment Video

Updated: Apr 12, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K

Identifying optimal biomarker combinations for treatment selection through randomized controlled trials.

Ying Huang1

  • 1Division of Public Health Sciences, Fred Hutchinson Cancer Research Center, Seattle, WA, USA Department of biostatistics, University of Washington, Seattle, WA, USA yhuang@fhcrc.org.

Clinical Trials (London, England)
|May 8, 2015
PubMed
Summary

This study introduces a new statistical method to identify optimal treatment selection rules using biomarkers. The approach improves upon existing methods by incorporating variable selection for better clinical outcome prediction.

Keywords:
BiomarkerRamp losstotal burdentreatment selectionvariable selection

More Related Videos

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Related Experiment Videos

Last Updated: Apr 12, 2026

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances
07:35

Selecting Multiple Biomarker Subsets with Similarly Effective Binary Classification Performances

Published on: October 11, 2018

8.1K
Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis
07:40

Preparation of Peripheral Blood Mononuclear Cell Pellets and Plasma from a Single Blood Draw at Clinical Trial Sites for Biomarker Analysis

Published on: March 20, 2021

18.8K
Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation
15:04

Potentiation of Anticancer Antibody Efficacy by Antineoplastic Drugs: Detection of Antibody-drug Synergism Using the Combination Index Equation

Published on: January 19, 2019

13.0K

Area of Science:

  • Biostatistics
  • Clinical Trial Methodology
  • Translational Bioinformatics

Background:

  • Biomarkers can personalize treatment recommendations to optimize clinical outcomes.
  • Current methods for deriving treatment-selection rules often rely on risk modeling.
  • Directly minimizing disease and treatment burden offers a more robust approach but presents computational challenges.

Purpose of the Study:

  • To extend existing algorithms for deriving marker-based treatment-selection rules.
  • To incorporate variable selection for handling a large number of candidate biomarkers.
  • To directly minimize an unbiased estimate of total disease and treatment burden.

Main Methods:

  • Developed a novel algorithm to minimize a weighted sum of Ramp loss, approximating 0-1 loss.
  • Employed a smooth and differentiable objective function for iterative minimization.
  • Integrated an L1 penalty and coordinate descent algorithm for feature selection.

Main Results:

  • The proposed estimator demonstrated comparable or superior performance to existing methods in simulations.
  • Variable selection capability significantly enhanced treatment-selection performance with numerous markers.
  • The method effectively identified relevant variables for treatment selection, outperforming penalized regression models.

Conclusions:

  • The proposed estimator offers an effective and conceptually simple approach for biomarker-based treatment selection.
  • This method has strong potential for clinical application in selecting and combining biomarkers.
  • Facilitates personalized medicine by optimizing treatment strategies based on individual patient characteristics.